Prognostic factors in acute lymphoblastic leukemia.*
| Host-Related . | Disease-Related . | Treatment-Related . |
|---|---|---|
| Age | White Blood Cell Count | Protocol |
| Gender | CNS disease | Early Response |
| Race | Mediastinal Mass | Day 7 marrow |
| Down syndrome | Splenomegaly | Day 14 marrow |
| Immunodeficiency | Hepatomegaly | Day 28 marrow |
| Renomegaly | Peripheral blasts | |
| Testicular Disease | Minimal residual disease | |
| Nutrition | Hemoglobin > 10 g/dL | CDRIII PCR |
| Compliance | Platelets < 100,000/mL | TCR PCR |
| Access | Visible adenopathy | Immunologic fingerprint |
| FAB Morphology | Combined PCR and Immunologic | |
| Pharmacogenetics | PAS Positivity | Fluoresecent in situ hybridization |
| GST variants | Labeling Index | Leukemic Colony-Forming Units |
| Pharmacogenomics | Prednisone Response | |
| T-cell lineage | ||
| Immature T-cell lineage | RBC Thioguanine Nucleotides | |
| B-lineage | Systemic thiopurine exposure | |
| CD 10 Negativity | Systemic methotrexate exposure | |
| Myeloid Antigen Positivity | Methotrexate polyglutamates | |
| Karyotype | MTT assay | |
| Hyperdiploidy | ||
| Hypodiploidy | ||
| +4, +10 | ||
| del 9p | ||
| +10, +17, +18 | ||
| 13q12-14 | ||
| 15(q13-15) | ||
| t(9;22) | ||
| t(4;11) | ||
| other t(11q23) | ||
| t(1;19) | ||
| balanced t(1;19) | ||
| TEL/AML1 | ||
| MLLr | ||
| Lactate Dehydrogenase | ||
| Glucocorticoid Receptor Number | ||
| Abbreviations: CNS, central nervous sytem; GST, glutathione S-transferase | ||
| Host-Related . | Disease-Related . | Treatment-Related . |
|---|---|---|
| Age | White Blood Cell Count | Protocol |
| Gender | CNS disease | Early Response |
| Race | Mediastinal Mass | Day 7 marrow |
| Down syndrome | Splenomegaly | Day 14 marrow |
| Immunodeficiency | Hepatomegaly | Day 28 marrow |
| Renomegaly | Peripheral blasts | |
| Testicular Disease | Minimal residual disease | |
| Nutrition | Hemoglobin > 10 g/dL | CDRIII PCR |
| Compliance | Platelets < 100,000/mL | TCR PCR |
| Access | Visible adenopathy | Immunologic fingerprint |
| FAB Morphology | Combined PCR and Immunologic | |
| Pharmacogenetics | PAS Positivity | Fluoresecent in situ hybridization |
| GST variants | Labeling Index | Leukemic Colony-Forming Units |
| Pharmacogenomics | Prednisone Response | |
| T-cell lineage | ||
| Immature T-cell lineage | RBC Thioguanine Nucleotides | |
| B-lineage | Systemic thiopurine exposure | |
| CD 10 Negativity | Systemic methotrexate exposure | |
| Myeloid Antigen Positivity | Methotrexate polyglutamates | |
| Karyotype | MTT assay | |
| Hyperdiploidy | ||
| Hypodiploidy | ||
| +4, +10 | ||
| del 9p | ||
| +10, +17, +18 | ||
| 13q12-14 | ||
| 15(q13-15) | ||
| t(9;22) | ||
| t(4;11) | ||
| other t(11q23) | ||
| t(1;19) | ||
| balanced t(1;19) | ||
| TEL/AML1 | ||
| MLLr | ||
| Lactate Dehydrogenase | ||
| Glucocorticoid Receptor Number | ||
| Abbreviations: CNS, central nervous sytem; GST, glutathione S-transferase | ||
Factors in bold face are those that are recognized as predictive of outcome in the majority of studies; those that are italicized are ones that are either no longer considered predictive or are no longer in general use.